MedTrace Logo

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

NCT05641324 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2024-02-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of ANV419 monotherapy followed by ANV419 in combination with lenalidomide plus low-dose dexamethasone or ANV419 in combination with daratumumab.

Conditions

Interventions

DRUG

ANV419

ANV419 administered by intravenous (IV) infusion

DRUG

Lenalidomide with low-dose dexamethasone

Lenalidomide and dexamethasone administered orally

DRUG

Daratumumab

Daratumumab administered by subcutaneous injection

Sponsors & Collaborators

  • Anaveon AG

    lead INDUSTRY

Principal Investigators

  • Eduard Gasal, MD · Anaveon AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-10
Primary Completion
2023-07-12
Completion
2023-07-12

Countries

  • Denmark
  • France
  • Germany
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05641324 on ClinicalTrials.gov